Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Zoetis (ZTS) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDrug Manufacturers - Specialty & GenericZTS

Closing price · Nov 19, 2026 $82.25 -3.9% on the day · -28.6% over 12 months 52-week range $68.64 – $129.63
Get ZTS alerts
Open-market purchases3 insiders$886K · last 12 months
Insiders selling1last 12 months
Reported sales$2.5M2 of 2 recent sales pre-planned (10b5-1)
In 15 seconds

Some insider buying ($886K), but sales were much larger ($2.5M) over the same 12 months.

Past insider buys here: 0 of 3 beat the S&P 500 over the next 90 days (small sample). See each one ↓

Label: Mixed: buying, heavier selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
Latest open-market trade

Purchase Frank A. Damelio, Director bought 6,650 shares at $75.39 ($501K).

Trade date
May 13, 2026
Disclosed to the SEC
May 13, 2026
Type
Open-market purchase (code P)

Read the original SEC filing ↗All ZTS insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

ZTS insider transactions (Form 4)

Open-market purchases and sales. 81 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
May 13SEC Frank A. DamelioDirectorFirst buy Buy 6,65021,458 held (+45%) $75.39 $501K +9.1% —
May 13SEC Paul BisaroDirectorFirst buy Buy 2,00027,862 held (+8%) $75.88 $152K +8.4% 37
May 12SEC Michael B. McCallisterDirectorFirst buy Buy 3,00024,524 held (+14%) $77.76 $233K +5.8% —
Feb 17SEC Kristin C. PeckCEO Sell Plan 10,800101,337 held (−10%) $127.55 $1.4M -35.5% —
Feb 17SEC Kristin C. PeckCEO Sell Plan 9,200112,137 held (−8%) $126.46 $1.2M -35.0% —
Historical context

Similar past setups: not applicable. There aren't enough comparable past cases for ZTS's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with ZTS in the Research Lab

Pre-set to ZTS's latest insider buy of $10K or more (May 13, 2026: Frank A. Damelio, Michael B. McCallister, Paul Bisaro, $886K). Tap to change anything.

All tools →

Share price and insider trades

ZTS closeInsider buyInsider sale
6080100120140DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-12EEarnings release filed 2026-05-07EEarnings release filed 2026-08-06Bought $233,273 on 2026-05-11 · Michael B. McCallisterBought $653,094 on 2026-05-13 · Frank A. Damelio, Paul BisaroSold $2,540,964 on 2026-02-17 · Kristin C. Peck
Bought, 12 months$886K
Sold, 12 months$2.5M
Insiders buying3
Insiders selling1

Zoetis insider trading at a glance (Nov 20, 2026): in the past 12 months, 3 insiders bought $886K and 1 sold $2.5M of ZTS stock on the open market, including a cluster buy that began May 11, 2026; P/E 12.1 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

ZTS insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $2.5M sold (2 trades)Q1 2026Q2 2026: $886K bought (3 trades)$886KQ2 2026Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0—0
Q2 2026$886K3—0
Q1 2026—0$2.5M2

Valuation, profit and volume

P/E (trailing)12.1Sector median 25.0
Market value$30.30BDrug Manufacturers - Specialty & Generic
Profit margin27.7%Revenue growth -0.2%
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit+$72KOn all tracked purchases +8.1%

Source: Yahoo Finance, as of Oct 8, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 3 Zoetis insiders reported open-market purchases totaling $886K, while 1 insider reported sales totaling $2.5M. The most recent cluster buy began on May 11, 2026, when 3 insiders bought a combined $886K. Among insiders with enough purchase history to measure, Paul Bisaro (Director) has the highest Insider Score at 37. 2 of 2 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ZTS earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 6, 2026 -1.3% None -2.3%S&P +0.5% +4.3%
May 7, 2026 -5.9% None -25.5%S&P +0.5% -4.1%
Feb 12, 2026 +3.0% None -1.6%S&P -1.5% -8.7%
Nov 4, 2025 +0.6% None -16.5%S&P -0.8% -1.5%
Aug 5, 2025 +2.2% None -3.5%S&P +0.3% +4.7%
May 6, 2025 +6.7% None -1.3%S&P -0.4% +9.1%
Feb 13, 2025 +2.0% None -9.4%S&P +1.1% +2.4%
Nov 4, 2024 -4.5% None -3.7%S&P +1.0% -0.3%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

ZTS short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 26% of volume sold short2026-08-27: 52% of volume sold short2026-08-28: 54% of volume sold short2026-08-31: 50% of volume sold short2026-09-01: 42% of volume sold short2026-09-02: 51% of volume sold short2026-09-03: 43% of volume sold short2026-09-04: 43% of volume sold short2026-09-08: 46% of volume sold short2026-09-09: 46% of volume sold short2026-09-10: 51% of volume sold short2026-09-11: 44% of volume sold short2026-09-14: 44% of volume sold short2026-09-15: 46% of volume sold short2026-09-16: 53% of volume sold short2026-09-17: 61% of volume sold short2026-09-18: 58% of volume sold short2026-09-21: 39% of volume sold short2026-09-22: 42% of volume sold short2026-09-23: 54% of volume sold short2026-09-24: 46% of volume sold short2026-09-25: 54% of volume sold short2026-09-28: 46% of volume sold short2026-09-29: 52% of volume sold short2026-09-30: 40% of volume sold short2026-10-01: 53% of volume sold short2026-10-02: 51% of volume sold short2026-10-05: 42% of volume sold short2026-10-06: 37% of volume sold short2026-10-07: 35% of volume sold short2026-10-08: 49% of volume sold short2026-10-09: 53% of volume sold short2026-10-12: 44% of volume sold short2026-10-13: 41% of volume sold short2026-10-14: 51% of volume sold short2026-10-15: 36% of volume sold short2026-10-16: 36% of volume sold short2026-10-19: 41% of volume sold short2026-10-20: 46% of volume sold short2026-10-21: 50% of volume sold short2026-10-22: 24% of volume sold short2026-10-23: 47% of volume sold short2026-10-26: 39% of volume sold short2026-10-27: 45% of volume sold short2026-10-28: 49% of volume sold short2026-10-29: 37% of volume sold short2026-10-30: 40% of volume sold short2026-11-02: 50% of volume sold short2026-11-03: 48% of volume sold short2026-11-04: 32% of volume sold short2026-11-05: 42% of volume sold short2026-11-06: 35% of volume sold short2026-11-09: 30% of volume sold short2026-11-10: 26% of volume sold short2026-11-11: 22% of volume sold short2026-11-12: 58% of volume sold short2026-11-13: 57% of volume sold short2026-11-16: 43% of volume sold short2026-11-17: 43% of volume sold short2026-11-18: 38% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 38%20-day average: 39%Prior 2 months: 46%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded ZTS

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Shelley M CapitoSenate Sold $1,001 - $15,000 Oct 21, 2026Nov 4, 2026 +4.0%
Markwayne MullinSenate Sold $15,001 - $50,000 Nov 10, 2025Dec 5, 2025 -30.3%

What happened after ZTS insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
May 13, 2026Paul BisaroDirector$152K +7.2%+7.4% vs S&P+7.0%+7.1% vs S&P+2.1%-2.0% vs S&P
May 13, 2026Frank A. DamelioDirector$501K +7.2%+7.4% vs S&P+7.0%+7.1% vs S&P+2.1%-2.0% vs S&P
May 12, 2026Michael B. McCallisterDirector$233K +2.6%+3.2% vs S&P+5.8%+5.9% vs S&P-2.1%-7.1% vs S&P

Insiders at Zoetis

InsiderBoughtSoldLast filingPast buys beat S&PScore
Kristin C. PeckCEO — $2.5M Feb 23, 2026 — —
Frank A. DamelioDirector $501K — Aug 11, 2026 — —
Michael B. McCallisterDirector $233K — Jun 11, 2026 — —
Paul BisaroDirector $152K — May 13, 2026 — 37
Julie FullerPresident — — Oct 2, 2026 — —
Mark StetterDirector — — May 26, 2026 — —
Louise M. ParentDirector — — May 21, 2026 — —
Kevin EschPresident — — May 1, 2026 — —
Keith SarbaughPresident — — Apr 1, 2026 — —
Gregory NordenDirector — — Mar 10, 2026 — —
Wetteny JosephCFO — — Feb 23, 2026 — —
Jamie BrannanPresident — — Feb 23, 2026 — —
Vanessa BroadhurstDirector — — Feb 23, 2026 — —
Gavin HattersleyDirector — — Feb 23, 2026 — —
Antoinette Renee LeatherberryDirector — — Feb 23, 2026 — —
Nicholas AshtonPresident — — Feb 23, 2026 — —
Roxanne LaganoPresident — — Feb 23, 2026 — —
Astorga Jeannette FerranPresident — — Feb 23, 2026 — —
Rimma DriscollPresident — — Feb 23, 2026 — —
Willie M. ReedDirector — — Feb 23, 2026 — —

Board links: companies that share insiders with ZTS

Directors and executives who filed Form 4s for ZTS and another company in the last 12 months.

See the map →
  • BLKBlackRock Kristin C. Peck CEO here · Director at BLK · latest filing Oct 2, 2026
  • DRCTDirect Digital Holdings Antoinette Renee Leatherberry Director here · Director at DRCT · latest filing Jun 29, 2026
  • DXCMDexcom Rimma Driscoll President here · Director at DXCM · latest filing Jun 1, 2026
  • HPEHewlett Packard Enterprise Frank A. Damelio Director here · Director at HPE · latest filing Aug 11, 2026
  • JNJJohnson & Johnson Vanessa Broadhurst Director here · Evp, Global Corp Affairs at JNJ · latest filing Jul 21, 2026
  • MKCMcCormick Gavin Hattersley Director here · Director at MKC · latest filing Oct 5, 2026
  • MYGNMyriad Genetics Paul Bisaro Director here · Director at MYGN · latest filing May 14, 2026
  • RPRXRoyalty Pharma Gregory Norden Director here · Director at RPRX · latest filing May 15, 2026
  • VTRSViatris Frank A. Damelio Director here · Director at VTRS · latest filing Aug 11, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

ZTS stock: common questions

Are Zoetis insiders buying ZTS stock?

In the past 12 months, 3 insiders reported open-market purchases of ZTS worth $886K. The latest was Director Frank A Damelio bought $501K of ZTS at $75.39 — first open-market purchase in our records; raises the stake by 45%.

Are Zoetis insiders selling ZTS stock?

1 insider reported sales worth $2.5M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ZTS's P/E ratio?

ZTS trades at about 12.1 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is ZTS's 52-week range?

Over the past year ZTS has traded between $68.64 and $129.63. It last closed at $82.25 on Nov 19, 2026.